| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Paulownin does not have a well-defined single pharmacological target, as it is a natural lignan with multiple biological activities. It has been reported to have anti-inflammatory, analgesic, immunity-modulating, and hypoglycemic activities. Paulownin also inhibits H. pylori cystathionine gamma-synthase (HpCGS) with IC50 values of 19 ± 2 μM. The compound has demonstrated activity against the MCF-7 breast cancer cell line with IC50 values of 14.0 μM. Its mechanisms of action may involve modulation of inflammatory pathways, inhibition of bacterial enzymes, and induction of apoptosis in cancer cells.
|
|---|---|
| ln Vitro |
Paulownin demonstrates potent in vitro activity against the MCF-7 breast cancer cell line with IC50 values of 14.0 μM. It also inhibits H. pylori cystathionine gamma-synthase (HpCGS) with IC50 values of 19 ± 2 μM. The compound has anti-inflammatory, analgesic, immunity-modulating, and hypoglycemic activities. These in vitro results indicate that paulownin has multiple pharmacological activities, including anticancer, antibacterial, and anti-inflammatory effects. The compound's low toxicity makes it an attractive candidate for further research.
|
| ln Vivo |
In vivo activity data for Paulownin are limited, as the compound is primarily used as a research tool. Its anti-inflammatory, analgesic, immunity-modulating, and hypoglycemic activities suggest potential applications in various disease models. However, comprehensive in vivo studies evaluating its pharmacokinetic properties, efficacy, and safety have not been extensively reported. The compound's low toxicity is a favorable property for potential in vivo applications. Further research is needed to assess its potential for in vivo use.
|
| Enzyme Assay |
In vitro enzyme/receptor binding experiments for Paulownin typically involve measuring its inhibitory activity against H. pylori cystathionine gamma-synthase (HpCGS) or other enzymes. The assay is performed by incubating the compound with the enzyme and measuring the inhibition of enzymatic activity. Dose-response curves are generated to calculate IC50 values. The compound's anti-inflammatory activity can also be assessed by measuring its effects on inflammatory mediators in cell-based assays. Its chemical properties are characterized using standard analytical methods such as HPLC and mass spectrometry.
|
| Cell Assay |
The in vitro cellular assay for Paulownin typically involves studying its effects on cancer cell lines, such as MCF-7 breast cancer cells. Cells are treated with various concentrations of paulownin, and cell viability is measured using MTT or similar assays. The IC50 for cell growth inhibition is calculated from dose-response curves. The compound's anti-inflammatory effects can be assessed by measuring cytokine production in activated immune cells. Cytotoxicity is assessed in parallel to ensure that the observed effects are not due to cell death. The compound's low toxicity is a notable property.
|
| Animal Protocol |
In vivo animal experiments for Paulownin would typically involve administering the compound to rodents via oral gavage or intraperitoneal injection. Cancer models, such as xenograft models, could be used to assess the compound's antitumor effects. Inflammation models could be used to assess its anti-inflammatory effects. Diabetes models could be used to assess its hypoglycemic activity. However, comprehensive in vivo studies have not been extensively reported. Further research is needed to evaluate its pharmacokinetic properties and efficacy in animal models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Paulownin have not been extensively characterized. With a molecular weight of 370.36, the compound is expected to have moderate lipophilicity and reasonable membrane permeability. However, detailed studies on its absorption, distribution, metabolism, and excretion are limited. The compound's low toxicity is a favorable property for potential in vivo applications. Further pharmacokinetic studies would be required to assess its potential for in vivo use.
|
| Toxicity/Toxicokinetics |
Toxicological data for Paulownin indicate that it has low toxicity. In vitro cytotoxicity assays typically show that the compound has a favorable safety profile, as it exhibits activity against cancer cells at concentrations that do not cause significant cytotoxicity to normal cells. Comprehensive in vivo toxicology studies, including acute and chronic toxicity, have not been extensively reported. Researchers handling this compound should follow standard safety protocols for handling natural products.
|
| References | |
| Additional Infomation |
Paulowniain has been reported to be found in Cleistanthus collinus, Markhamia stipulata, and other organisms with relevant data. See also: (+)-Paulowniain (note moved to).
Paulownin is a research compound that has not entered clinical trials or received regulatory approval for therapeutic use. It is primarily used as a tool compound to study the pharmacological activities of lignans, including anticancer, anti-inflammatory, and antimicrobial effects. The compound's multiple biological activities and low toxicity make it a valuable candidate for further pharmacological development. Additional research is needed to fully elucidate its mechanisms of action and evaluate its potential therapeutic applications. |
| Molecular Formula |
C20H18O7
|
|---|---|
| Molecular Weight |
370.3527
|
| Exact Mass |
370.105
|
| CAS # |
13040-46-5
|
| PubChem CID |
3084131
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
555.0±50.0 °C at 760 mmHg
|
| Melting Point |
106 ° C
|
| Flash Point |
289.5±30.1 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.662
|
| LogP |
3.36
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
27
|
| Complexity |
573
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1[C@@H]2[C@H](OC[C@@]2([C@H](O1)C3=CC4=C(C=C3)OCO4)O)C5=CC6=C(C=C5)OCO6
|
| InChi Key |
CAQZFLPWHBKTTR-WNISUXOKSA-N
|
| InChi Code |
InChI=1S/C20H18O7/c21-20-8-23-18(11-1-3-14-16(5-11)26-9-24-14)13(20)7-22-19(20)12-2-4-15-17(6-12)27-10-25-15/h1-6,13,18-19,21H,7-10H2/t13-,18-,19-,20-/m1/s1
|
| Chemical Name |
(3R,3aS,6S,6aR)-3,6-bis(1,3-benzodioxol-5-yl)-3,4,6,6a-tetrahydro-1H-furo[3,4-c]furan-3a-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~270.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.75 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.75 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.75 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7001 mL | 13.5007 mL | 27.0015 mL | |
| 5 mM | 0.5400 mL | 2.7001 mL | 5.4003 mL | |
| 10 mM | 0.2700 mL | 1.3501 mL | 2.7001 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
